Not applicableStudy completedNCT05898412What this trial is testingRetrospective Study on Characteristics and Outcomes in Hospitalised Patients Treated With OndexxyaWho this might be right forHemorrhage AstraZeneca 217
Post-approval studies (Phase 4)Looking for participantsNCT07521332What this trial is testingApixaban-PK Trial: Preventing Portal Hypertension Complications in CirrhosisWho this might be right forCirrhosisEsophageal and Gastric VaricesAscites+3 more Asian Institute Of Medical Sciences 220
Large-scale testing (Phase 3)Ended earlyNCT02179177What this trial is testingApixaban in Patients With Sickle Cell DiseaseWho this might be right forVaso-occlusive CrisisReduction in HospitalizationsSickle Cell Disease Nirmish Shah 16
Testing effectiveness (Phase 2)Study completedNCT00402467What this trial is testingAn Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging StudyWho this might be right forVenous Thromboembolism Bayer 613
Not applicableStudy completedNCT06147830What this trial is testingDescribe the Characteristics, Health Care Interventions and Outcomes of Patients With Major Bleedings in the Presence of Factor Xa Inhibitor TreatmentWho this might be right forMajor Bleeding AstraZeneca 2,202
Testing effectiveness (Phase 2)Study completedNCT00973323What this trial is testingBAY59-7939 Japanese in Atrial Fibrillation (2nd)Who this might be right forAtrial Fibrillation Bayer 100
Testing effectiveness (Phase 2)Study completedNCT00973245What this trial is testingBAY59-7939 in Atrial Fibrillation Once Daily (OD)Who this might be right forAtrial Fibrillation Bayer 102
Large-scale testing (Phase 3)Study completedNCT00439777What this trial is testingOral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE StudyWho this might be right forPulmonary Embolism Bayer 4,833
Large-scale testing (Phase 3)Study completedNCT01181102What this trial is testingDU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee ArthroplastyWho this might be right forVenous Thromboembolism Daiichi Sankyo Co., Ltd. 716
Testing effectiveness (Phase 2)Study completedNCT00742859What this trial is testingPhase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to WarfarinWho this might be right forAtrial Fibrillation Portola Pharmaceuticals 508
Post-approval studies (Phase 4)Ended earlyNCT02945280What this trial is testingApixaban for Routine Management of Upper Extremity Deep Venous ThrombosisWho this might be right forDeep Venous ThrombosisUpper Extremity Deep Venous ThrombosisThrombus+2 more Intermountain Health Care, Inc. 52
Testing effectiveness (Phase 2)Study completedNCT04640181What this trial is testingFactor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT)Who this might be right forCovid19 St. David's HealthCare 150
Post-approval studies (Phase 4)Looking for participantsNCT04258488What this trial is testingLong-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve ReplacementWho this might be right forAORTIC VALVE DISEASESThromboembolism Joon Bum Kim 1,300
Testing effectiveness (Phase 2)Study completedNCT00839826What this trial is testingODiXahip - a Phase IIa Dose Escalating Proof of Principle TrialWho this might be right forThromboembolismPrevention Bayer 641
Testing effectiveness (Phase 2)Study completedNCT01203072What this trial is testingA Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee ArthroplastyWho this might be right forVenous ThromboembolismDeep Vein ThrombosisTotal Knee Arthroplasty Daiichi Sankyo Co., Ltd. 523
Testing effectiveness (Phase 2)Study completedNCT00839163What this trial is testingOral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)Who this might be right forVenous ThrombosisDeep Vein Thrombosis Bayer 613
Testing effectiveness (Phase 2)Study completedNCT00133731What this trial is testingThe SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary InterventionWho this might be right forAngioplasty, Transluminal, Percutaneous Coronary Sanofi 947
Large-scale testing (Phase 3)Study completedNCT01181167What this trial is testingDU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip ArthroplastyWho this might be right forPreventionVenous Thromboembolism Daiichi Sankyo Co., Ltd. 610
Testing effectiveness (Phase 2)Study completedNCT00408239What this trial is testingFactor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee ReplacementWho this might be right forThromboembolism Astellas Pharma Inc 367
Testing effectiveness (Phase 2)Study completedNCT00395772What this trial is testingOnce-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein ThrombosisWho this might be right forVenous Thromboembolism Bayer 543